By Pablo Erbar
Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) announced that it has begun Phase 1 clinical trials to study Actimab-M in the treatment of multiple myeloma. Although this disease is treatable, it is not considered curable. Hence, despite undergoing treatment, patients will eventually relapse as they succumb to this fatal illness.
Actinium Pharmaceuticals Inc (NYSEMKT:ATNM)’s latest product is comprised of HuM-195, which targets the monoclonal antibody CD33, and an alpha-particle emitter known as actinium 225. According to recent research, the antigen CD33 can be found in the malignant cells of approximately 25%-35% of all multiple myeloma patients, making it a great target for treatment. Actinium’s innovative approach to treating the disease consists of attacking CD33 directly.
Thanks to its novel approach, the biopharmaceutical company’s drug Actimab-M looks promising in terms of addressing this issue. During the Phase 1 clinical trials, Actimab-M will be issued to patients which have already been subject to 3 previous treatment regimens and continue displaying progressive multiple myeloma.
According to Dr. M. Yair Levy of Texas Oncology – Baylor Charles A. Sammons Cancer Center, “relapsed and refractory multiple myeloma is an area of high unmet medical need that we hope to address with Actimab-M.” The targeted treatment may provide not only a useful tool in the treatment of the fatal disease, but could also represent a significant step for Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), which hopes to expand its clinical pipeline.
Disclosures: The author, Pablo Erbar, holds no interest in any of the securities or entities mentioned above.